Ionis Pharmaceuticals (MEX:IONS) Cash per Share: MXN216.44 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:IONS Ionis Pharmaceuticals Inc MEX:IONS
71 GF Score
Price MXN1,150.00
GF Value MXN1,028.27
! 5 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals Cash per Share?

Ionis Pharmaceuticals MEX:IONS 71 Cash per Share is MXN216.44 as of Jun. 2026. GuruFocus rates MEX:IONS with a GF Score™ of 71/100 and a GF Value™ of MXN1,028.27. The stock has 5 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Ionis Pharmaceuticals's Cash per Share for the quarter that ended in Jun. 2026 was MXN216.44.

Ionis Pharmaceuticals  (MEX:IONS) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Ionis Pharmaceuticals Cash per Share Related Terms

Ionis Pharmaceuticals Cash per Share Historical Data

* Premium members only.

The historical data trend for Ionis Pharmaceuticals's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals Cash per Share Chart

Ionis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 307.25 272.68 274.15 303.46 295.21

Ionis Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 270.85 255.03 295.21 208.60 216.44
MEX:IONS
71GF Score
Ionis Pharmaceuticals Inc MEX:IONS
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ionis Pharmaceuticals Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Ionis Pharmaceuticals's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=48209.109/163
=295.21

Ionis Pharmaceuticals's Cash per Share for the quarter that ended in Jun. 2026 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=35850.454/166
=216.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of MXN216.44 mean?
Ionis Pharmaceuticals (MEX:IONS) has a Cash per Share of MXN216.44 as of Jun. 2026. Cash per share is the per-share value of a company's available cash. View historical data for Ionis Pharmaceuticals and its competitors.
Is Ionis Pharmaceuticals' Cash per Share too high?
Ionis Pharmaceuticals' current Cash per Share is MXN216.44. Overall, Ionis Pharmaceuticals has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Cash per Share compare to KYMR and PRAX?
Ionis Pharmaceuticals' Cash per Share of MXN216.44 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Biotechnology company?
A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current Cash per Share is MXN216.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Ionis Pharmaceuticals (MEX:IONS) has a current Cash per Share of MXN216.44. The stock's GF Value™ is MXN1,028.27, compared to a current price of MXN1,150.00 — trading 11.8% above its estimated fair value. The current Cash per Share is MXN216.44. Ionis Pharmaceuticals' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For Ionis Pharmaceuticals (MEX:IONS), the current Cash per Share is MXN216.44 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ionis Pharmaceuticals (MEX:IONS) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of MXN1,150.00 is trading 11.8% above its estimated GF Value™ of MXN1,028.27.

Key valuation signals for MEX:IONS:

  • Cash per Share: MXN216.44
  • GF Value™: MXN1,028.27 vs. price of MXN1,150.00 (11.8% above fair value)
  • GF Score™: 71/100 with 5 warning signs

No single metric tells the full story. See the MEX:IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ionis Pharmaceuticals Business Description

Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
71GF Score

Get the complete analysis for MEX:IONS

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,150.00
Price
MXN1,028.27
GF Value